Early detection of cancer.


CancerDetect™ is our proprietary liquid biopsy platform tailored for the early detection of cancer recurrence post-surgery. This innovative technology pinpoints unique genetic mutations in surgically removed cancer tissues, laying the groundwork for a personalized genetic panel. The custom panel is designed for the meticulous monitoring of Minimal Residual Disease (MRD), postoperatively.

By employing this personalized genetic panel testing, we can forecast potential cancer relapse months in advance compared to traditional imaging techniques. Our forward-thinking strategy ensures the early identification of recurrences, allowing for prompt adjustments in treatment strategies based on test results. Ultimately, CancerDetect™ is pivotal in improving patient outcomes by anticipating cancer progression and fine-tuning chemotherapy regimens.

Assay Type Tumor tissue sequencing
Targeted hybrid capture NGS based on proprietary HQS™ technology
Sample Requirement Tissue : FFPE (10μm x 10 sections) or FF
Blood : >20mL of whole blood
Targets Customized panel of up to 100 targets
Detected Alterations SNVs and Indels
Limit of Detection 0.005% ~ 0.0005% ctDNA fraction
  • Cancer-related variant detection

    Cancer-related variant detection

  • Tissue-informed personalized panel design

    Tissue-informed personalized panel design

  • Recurrence monitoring

    Recurrence monitoring

Clinical Validation - MRD Detection in Colorectal Cancer

Based on an ongoing large cohort multi-center study), MRD positivity as determined by the CancerDetect™ assay showed a strong association with poor recurrence free survival.

Reference(1): Sunghoon Heo, Sae-Won Han, Tae-You Kim et. al Personalized circulating tumor DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer. British Journal of Cancer 2023

CancerDetect™ Test Process

1. Sequencing of tumor tissue and matched whole blood

2. Design of bespoke panel including patient-specific biomarkers from tissue analysis and additional therapeutic targets of choice

3. Longitudinal surveillance through serial liquid biopsy testing based on ultradeep targeted hybridization capture NGS to detect
presence of ctDNA

  • 1) Select patient-specific somatic mutations from tissue samples

  • 2) Establish target capture BSP(bespoke panel) for detecting the selected patient-specific somatic mutations

  • 3) Extract cfDNA from the whole blood (20mL) and use BSP to perform target capture sequencing to detect MRD